Amelioration of ovalbumin-induced lung inflammation in a mouse model by Trichinella spiralis novel cystatin
3
Issued Date
2023-11-01
Resource Type
ISSN
09728988
eISSN
22310916
Scopus ID
2-s2.0-85204960659
Journal Title
Veterinary World
Volume
16
Issue
11
Start Page
2366
End Page
2373
Rights Holder(s)
SCOPUS
Bibliographic Citation
Veterinary World Vol.16 No.11 (2023) , 2366-2373
Suggested Citation
Thammasonthijarern N., Boonnak K., Reamtong O., Krasae T., Thankansakul J., Phongphaew W., Ampawong S., Adisakwattana P. Amelioration of ovalbumin-induced lung inflammation in a mouse model by Trichinella spiralis novel cystatin. Veterinary World Vol.16 No.11 (2023) , 2366-2373. 2373. doi:10.14202/vetworld.2023.2366-2373 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/101469
Title
Amelioration of ovalbumin-induced lung inflammation in a mouse model by Trichinella spiralis novel cystatin
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background and Aims: Asthma, a chronic disease affecting humans and animals, has recently become increasingly prevalent and steadily widespread. The alternative treatment of asthma using helminth infections or helminth-derived immunomodulatory molecules (IMs) has been evaluated and demonstrated significant amelioration of disease severity index in vitro and in vivo. Trichinella spiralis, a parasitic nematode and its IMs, elicits a potential to relieve asthma and other immune-related disorders. In this study, we investigated the immunomodulatory function of recombinant T. spiralis novel cystatin (rTsCstN) in ameliorating acute inflammatory asthma disorders in a murine model. Materials and Methods: Female BALB/c mice were sensitized using intraperitoneal injection of ovalbumin (OVA)/alum and subsequently challenged with intranasal administration of OVA alone or OVA + rTsCstN for 3 consecutive days, producing OVA-induced allergic asthma models. To evaluate the therapeutic efficacy of rTsCstN, the inflammatory cells and cytokines in bronchoalveolar lavage fluid (BALF) and OVA-specific immunoglobulin E levels in serum were assessed. Histological alterations in the lung tissues were determined by hematoxylin and eosin (H&E) staining and eventually scored for the extent of inflammatory cell infiltration. Results: The asthmatic mouse models challenged with OVA + rTsCstN demonstrated a significant reduction of eosinophils (p < 0.01), macrophages (p < 0.05), and cytokines tumor necrosis factor-α (p < 0.05) and interferon (IFN)-γ (p < 0.05) in BALF when compared with the mice challenged with OVA alone. However, the levels of interleukin (IL)-4 and IL-10 remained unchanged. Histological examination revealed that mice administered OVA + rTsCstN were less likely to have inflammatory cell infiltration in their perivascular and peribronchial lung tissues than those administered OVA alone. Conclusion: Recombinant T. spiralis novel cystatin demonstrated immunomodulatory effects to reduce severe pathogenic alterations in asthma mouse models, encouraging a viable alternative treatment for asthma and other immunoregulatory disorders in humans and animals in the future.